+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 254 Actively Recruiting clinical trials

I

Actively Recruiting

Healthy Volunteer

Researchers are working to create and use a comprehensive database focused on intracranial aneurysms IA. This project collects and studies clinical history, imaging data, biological samples, and other information to understand factors linked to the formation and rupture of aneurysms. They aim to identify genetic, environmental, and anatomical markers, as well as evaluate outcomes from different treatment strategies and improve patient care protocols. Participants include patients with diagnosed aneurysms, both ruptured and unruptured, family members of affected individuals, and healthy volunteers. Data collected involves detailed clinical records, imaging scans like MRI angiography and CT angiography, and various biological samples such as blood, cerebrospinal fluid, saliva, and stool. Consent covers access to medical records, use of biological samples, and potential future research uses including genetic analyses. During the study, participants provide health and lifestyle information, imaging data, and biological samples. Researchers will monitor multiple long-term outcomes including disease progression, life expectancy, quality of life, neurological and cognitive status, and treatment effects over periods up to 20 years. Data confidentiality is maintained, and participants can withdraw at any time without affecting their medical care. The study aims to validate disease models and support advances in aneurysm management and research.

Age: 18Years +All Genders
22 locations
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
S

Actively Recruiting

Researchers are studying sacituzumab tirumotecan, alone or combined with other treatments, to understand its safety and how it affects certain advanced or unresectable gastrointestinal cancers. These include colorectal cancer, pancreatic ductal adenocarcinoma, and biliary tract cancer. The study aims to evaluate how well the cancer responds to treatment and to monitor any side effects or adverse events over time. Participants will receive sacituzumab tirumotecan either as a single agent or combined with chemotherapy, cisplatin, and pembrolizumab in different dosing schedules. Treatments are given by intravenous infusions every 2 or 3 weeks depending on the study group, continuing until the cancer worsens or treatment is not tolerated. Rescue medications and supportive care are provided to manage side effects during the treatment period. Throughout the study, participants will be closely monitored with regular visits for safety and effectiveness assessments. Researchers will track dose-limiting toxicities, adverse events, treatment discontinuations, and tumor response using established criteria. The study may last up to approximately 63 months, allowing long-term observation of survival and progression-free outcomes. Participants will also receive various laboratory tests and supportive care as needed during this period.

Age: 18Years +All GendersPhase 1Phase 2
55 locations
S

Actively Recruiting

Researchers are evaluating if ifinatamab deruxtecan I-DXd, an antibody-drug conjugate, can treat people with advanced esophageal squamous cell carcinoma ESCC who have not responded to previous treatments. The study aims to find out how many participants experience cancer shrinkage or disappearance after receiving I-DXd. This trial is a phase 2, open-label study focusing on participants with unresectable locally advanced or metastatic ESCC. Participants receive I-DXd through an intravenous infusion every 3 weeks. Treatment continues until the cancer progresses or other discontinuation criteria are met. The study includes a single group where all participants receive I-DXd. Rescue medications such as 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids may be given as needed according to approved guidelines. Throughout the study, participants are regularly monitored for tumor response, side effects, and overall health. Researchers assess the objective response rate up to about 14 months, as well as secondary outcomes including duration of response, progression-free survival, overall survival, and adverse events. The total study duration spans up to approximately 26 months, allowing for ongoing safety evaluations and follow-up.

Age: 18Years +All GendersPhase 1Phase 2
32 locations
P

Actively Recruiting

Researchers are studying MK-7262, a trial medicine designed to lower Lipoproteina Lpa levels in the blood. The study aims to learn about the effects of MK-7262 alone and in combination with another trial medicine called enlicitide, which belongs to a group of medicines that lower low-density lipoprotein cholesterol LDL-C. This Phase 2 clinical trial evaluates the ability of these medicines to reduce Lpa and LDL-C levels and assesses their safety and tolerability. Participants will be randomly assigned to one of four groups MK-7262 with enlicitide, MK-7262 alone, enlicitide alone, or placebo for both medicines. All treatments are given orally once daily for up to approximately 12 weeks. The study is double-blind with placebo controls, and the medicines are taken as coated tablets. The trial monitors effects at specific time points including weeks 8 and 12. During the trial, participants will undergo blood tests to measure changes in Lpa and LDL-C levels from baseline. Researchers will track adverse events and monitor safety for up to about 20 weeks. The primary outcomes include percent changes in Lpa and LDL-C at week 8 and the number of participants experiencing side effects or discontinuing treatment due to side effects. Participation lasts for the treatment period and follow-up assessments.

Age: 18Years +All GendersPhase 2
76 locations
S

Actively Recruiting

Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.

Age: 18Years +FEMALEPhase 3
167 locations
C

Actively Recruiting

Researchers are evaluating whether combining ceftazidime with or without avibactam and fosfomycin leads to better clinical outcomes compared to ceftazidime alone in adults hospitalized with suspected severe Gram-negative bacterial infections. This phase 3 clinical trial aims to see if adding fosfomycin shortens the time to recovery as measured by normalization of quick Sequential Organ Failure Assessment qSOFA parameters and a significant drop in C-reactive protein CRP, a marker of inflammation. The study also monitors the safety of this combination treatment. Participants will be randomly assigned to one of two groups. The intervention group receives intravenous ceftazidime with or without avibactam plus fosfomycin, while the control group receives ceftazidime with or without avibactam plus a placebo infusion. Treatment is given for about three days, typically three times daily, with adjustments based on kidney function. The addition of avibactam depends on the presence of resistant bacteria as determined by the physician. Fosfomycin or placebo is given alongside in matching schedules. During the study, participants will provide extra blood samples to measure CRP levels and will be monitored in hospital or contacted by phone after discharge up to day 28 for follow-up questions. Researchers measure the time from treatment start until qSOFA parameters normalize and CRP levels decrease by half. Safety is closely watched by tracking adverse events during treatment and shortly afterward. The total participation spans the initial treatment and follow-up period to assess recovery and tolerability.

Age: 18Years +All GendersPhase 3
1 location
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a mentalization-based prevention program aimed at improving well-being and mental health in children aged 8 to 10 years and their families across four European countries Germany, Lithuania, Spain, and Switzerland. The study is designed as a partially randomized controlled trial and investigates how multi-level interventions involving children, parents, and teachers can promote mental health, reduce stigma, enhance help-seeking behavior, and improve classroom climate and parenting skills. The program includes a universal prevention workshop delivered at schools for all children, focusing on mental health awareness and peer support skills. Parents receive one of two different intervention trainings or a parenting guidebook one group attends 10 weekly sessions of the Lighthouse Program targeting secure attachment and reflective parenting behaviors, and another group participates in 6 bi-weekly Mentalization Based Skills Training sessions focusing on attentional control and emotion regulation. An active control group receives a parenting guidebook, while a passive control group participates in follow-up assessments without intervention. Participants will be involved in data collection at multiple time points baseline, post-intervention at 3 months, and follow-ups at 6 and 12 months. Assessments include questionnaires measuring childrens and parents well-being and mental health, parental efficacy and stress, classroom climate, teaching efficacy, and mental health stigma. Focus groups after the post-assessment will gather feedback on implementation and satisfaction. The study aims to follow 5,000 children, their parents, and teachers over a year to evaluate long-term program effects.

Age: 8Years +All GendersPhase Not Applicable
4 locations
E

Actively Recruiting

Healthy Volunteer

Hypertension is a leading risk factor for cardiovascular diseases and is often undetected because it shows no symptoms. Researchers are evaluating the performance and acceptance of the Hilo band, a cuffless blood pressure device that uses pulse wave analysis to estimate blood pressure and heart rate. This study focuses on young people aged 14 to 35, comparing the Hilo band with the traditional 24-hour Ambulatory Blood Pressure Monitoring ABPM, especially assessing both daytime and nighttime blood pressure readings. The study is a multi-center, non-interventional performance evaluation involving 40 young participants from three populations adolescents and young adults with a clinical indication for 24-hour ABPM, and healthy volunteers aged 21 to 35. Participants will use both the Hilo band and the 24-hour ABPM device over a 24-hour period, with additional assessments over three days. The Hilo band is designed to be comfortable, non-invasive, and suitable for long-term blood pressure monitoring, offering a potential alternative to the bulky and uncomfortable 24-hour ABPM cuff. Participants will be monitored for 24 hours with the 24-hour ABPM as the reference method to evaluate systolic and diastolic blood pressure measurements. Researchers will also assess the consistency of Hilo band readings over three days, its ability to classify hypertension, and participant and physician satisfaction with the device. The study includes continuous blood pressure measurements and satisfaction evaluations, aiming to provide data on the usefulness of the Hilo band in young, active populations over the course of the study.

Age: 14Years - 35YearsAll Genders
2 locations
S

Actively Recruiting

This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.

Age: 50Years - 80YearsAll GendersPhase 2
140 locations

1-10 of 254

1